November 21, 2016 - By Vivian Park · 0 Comments
The stock of Vermillion Incorporated (NASDAQ:VRML) registered a decrease of 60.41% in short interest. VRML’s total short interest was 202,000 shares in November as published by FINRA. Its down 60.41% from 510,200 shares, reported previously. With 28,000 shares average volume, it will take short sellers 7 days to cover their VRML’s short positions. The short interest to Vermillion Incorporated’s float is 0.88%. The stock increased 1.46% or $0.02 on November 18, hitting $1.2. Vermillion, Inc. (NASDAQ:VRML) has declined 22.07% since April 19, 2016 and is downtrending. It has underperformed by 25.93% the S&P500.
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The company has a market cap of $59.92 million. The Firm is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It currently has negative earnings. It sells OVA1 risk of malignancy test for pelvic mass disease .
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.60, from 0.4 in 2016Q1. The ratio is positive, as 4 funds sold all Vermillion, Inc. shares owned while 6 reduced positions. 1 funds bought stakes while 3 increased positions. They now own 19.63 million shares or 1.76% less from 19.98 million shares in 2016Q1.
The Missouri-based Cutter And Brokerage Inc has invested 0.01% in Vermillion, Inc. (NASDAQ:VRML). Moreover, Vanguard Gru Inc has 0% invested in Vermillion, Inc. (NASDAQ:VRML) for 596,498 shares. Blackrock Investment Management Limited Liability Co has 0% invested in the company for 4,390 shares. Trellus Mngmt Com Ltd Liability Corp last reported 181,845 shares in the company. Barclays Public Ltd Com accumulated 0% or 6,000 shares. Geode Capital Ltd Liability Corporation has invested 0% of its portfolio in Vermillion, Inc. (NASDAQ:VRML). Renaissance Techs Limited Liability Corp last reported 0% of its portfolio in the stock. Blackrock Fund Advsrs holds 0% of its portfolio in Vermillion, Inc. (NASDAQ:VRML) for 59,704 shares. Birchview Capital Ltd Partnership accumulated 2.72 million shares or 2.19% of the stock. Natl Bank Of America Corporation De holds 102 shares or 0% of its portfolio. The New York-based M&T Bank has invested 0% in Vermillion, Inc. (NASDAQ:VRML). Morgan Stanley holds 0% of its portfolio in Vermillion, Inc. (NASDAQ:VRML) for 42,448 shares. The California-based California Employees Retirement Systems has invested 0% in Vermillion, Inc. (NASDAQ:VRML). Morgens Waterfall Vintiadis And Inc has 1.00 million shares for 1.03% of their US portfolio. Hightower Advisors Ltd Company holds 166,700 shares or 0% of its portfolio.
Vermillion, Inc., incorporated on May 23, 2000, is a diagnostic service and bio-analytic solutions provider. The Firm is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Firm sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). The Company’s OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. The Firm developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated.
More notable recent Vermillion, Inc. (NASDAQ:VRML) news were published by: Prnewswire.com which released: “Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the …” on September 01, 2016, also Prnewswire.com with their article: “Vermillion CEO to Present at Women in Bio – New York” published on October 19, 2016, Equitiesfocus.com published: “Vermillion, Inc. (NASDAQ:VRML) Quarterly EPS From Continuing Operations Stands …” on November 20, 2016. More interesting news about Vermillion, Inc. (NASDAQ:VRML) were released by: Prnewswire.com and their article: “ASPiRA LABs Partners with New York Yankees Manager Joe Girardi for Ovarian …” published on September 07, 2016 as well as Prnewswire.com‘s news article titled: “Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman …” with publication date: December 16, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park